92 related articles for article (PubMed ID: 8875747)
1. Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels.
Ozata M; Bolu E; Sengul A; Tasar M; Beyhan Z; Corakci A; Gundogan MA
Thyroid; 1996 Aug; 6(4):283-8. PubMed ID: 8875747
[TBL] [Abstract][Full Text] [Related]
2. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
[TBL] [Abstract][Full Text] [Related]
3. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.
De Bellis A; Bizzarro A; Gattoni A; Romano C; Di Martino S; Sinisi AA; Abbadessa S; Bellastella A
J Clin Endocrinol Metab; 1995 Jul; 80(7):2118-21. PubMed ID: 7541801
[TBL] [Abstract][Full Text] [Related]
4. Soluble intercellular adhesion molecule-1 (sICAM-1) in Graves' disease.
Balázs C; Kiss E
Acta Microbiol Immunol Hung; 1994; 41(4):451-6. PubMed ID: 7866729
[TBL] [Abstract][Full Text] [Related]
5. Soluble intercellular adhesion molecule-1 concentrations in patients with subacute thyroiditis and in patients with Graves' disease with or without ophthalmopathy.
Ozata M; Bolu E; Sengül A; Altinsoy HI; Turan M; Corakci A; Hacibektasoglu A; Gundogan MA
Endocr J; 1996 Oct; 43(5):517-25. PubMed ID: 8980891
[TBL] [Abstract][Full Text] [Related]
6. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
De Bellis A; Sansone D; Coronella C; Conte M; Iorio S; Perrino S; Battaglia M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866
[TBL] [Abstract][Full Text] [Related]
7. Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases.
Heufelder AE; Bahn RS
Clin Exp Immunol; 1993 May; 92(2):296-302. PubMed ID: 8097976
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic role of adhesion molecules sELAM-1 and sICAM-1 in glucocorticoid therapy of active ophthalmopathy].
Modelska-Ziółkiewicz A; Gembicki M; Bednarek J; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):469-75. PubMed ID: 14768175
[TBL] [Abstract][Full Text] [Related]
9. Smoking and disease severity are independent determinants of serum adhesion molecule levels in Graves' ophthalmopathy.
Wakelkamp IM; Gerding MN; van der Meer JW; Prummel MF; Wiersinga WM
Clin Exp Immunol; 2002 Feb; 127(2):316-20. PubMed ID: 11876756
[TBL] [Abstract][Full Text] [Related]
10. Effect of octreotide treatment on Graves' ophthalmopathy.
Uysal AR; Corapçioğlu D; Tonyukuk VC; Güllü S; Sav H; Kamel N; Erdoğan G
Endocr J; 1999 Aug; 46(4):573-7. PubMed ID: 10580750
[TBL] [Abstract][Full Text] [Related]
11. [Usefulness of soluble ICAM-1 measurements for the evaluation of the disease activity and efficiency of therapy in patients with infiltrative Graves' ophthalmopathy].
Kulig G; Pilarska K; Kulig J; Krzyzanowska-Swiniarska B; Robaczyk M; Baraniak A
Pol Arch Med Wewn; 2002 Dec; 108(6):1161-9. PubMed ID: 12687928
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease.
Sonnet E; Massart C; Gibassier J; Allannic H; Maugendre D
J Endocrinol Invest; 1999 Jun; 22(6):430-5. PubMed ID: 10435852
[TBL] [Abstract][Full Text] [Related]
13. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
[TBL] [Abstract][Full Text] [Related]
14. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
15. Graves' dermopathy: does octreotide scintigraphy predict the response to octreotide treatment?
Kuyvenhoven JP; van der Pijl JW; Goslings BM; Wiersinga WM
Thyroid; 1996 Oct; 6(5):385-9. PubMed ID: 8936660
[TBL] [Abstract][Full Text] [Related]
16. Soluble endothelium-associated adhesion molecules in patients with Graves' disease.
Wenisch C; Myskiw D; Parschalk B; Hartmann T; Dam K; Graninger W
Clin Exp Immunol; 1994 Nov; 98(2):240-4. PubMed ID: 7525128
[TBL] [Abstract][Full Text] [Related]
17. The evolution of Graves' ophthalmopathy during treatment with antithyroid drug alone and combined with triiodothyronine.
Bromberg N; Romaldini JH; Werner RS; Sgarbi JA; Werner MC
J Endocrinol Invest; 1992 Mar; 15(3):191-5. PubMed ID: 1624679
[TBL] [Abstract][Full Text] [Related]
18. Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism.
Wenisch C; Myskiw D; Gessl A; Graninger W
J Clin Endocrinol Metab; 1995 Jul; 80(7):2122-6. PubMed ID: 7541802
[TBL] [Abstract][Full Text] [Related]
19. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy.
Kung AW; Michon J; Tai KS; Chan FL
Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659
[TBL] [Abstract][Full Text] [Related]
20. [Soluble forms of adhesion molecules sELAM-1 and sICAM-1 in Graves disease and toxic nodular goiter].
Modelska-Ziółkiewicz A; Gembicki M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):463-8. PubMed ID: 14768174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
